Relationship between serum cholesterol levels and meta-chlorophenylpiperazine-induced cortisol responses in healthy men and women

Terao, Takeshi; Nakamura, Jun; Yoshimura, Reiji; Ohmori, Osamu; Takahashi, Norito; Kojima, Hideki; Soeda, Shuji; Shinkai, Takahiro; Nakano, Hirofumi; Okuno, Takeo

doi:10.1016/s0165-1781(00)00197-9

Cited by 53 publications

(41 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-chlorophenylpiperazine (m-CPP) is a metabolite of the antidepressant trazodone that binds to a number of serotonergic receptors, primarily the 5-HT2a and -2c receptors, resulting in prolactin and cortisol secretion [49]. Thus, the degree of cortisol release to m-CPP is thought to reflect the sensitivity of the serotonergic receptors.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, the degree of cortisol release to m-CPP is thought to reflect the sensitivity of the serotonergic receptors. Two studies of healthy young adults reveal serum cholesterol levels to be positively correlated with the cortisol response to m-CPP, suggesting that higher cholesterol levels are associated with a more sensitive serotonergic receptor [49,50]. However, in depressed patients, a greater sensitivity of serotonergic receptors, as evident by an elevated secretion of cortisol or prolactin after administration of d-fenfluramine, has been found to confer a good prognosis to treatment in two studies [51,52].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Cholesterol in Treatment-Resistant Depression

et al. 2003

View full text Add to dashboard Cite

Objective: Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (≧200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). Methods: Ninety-two patients with TRD entered a 6-week open trial of NT. Baseline cholesterol levels were randomly collected for 59 of these patients. Controlling for age and gender, we compared baseline cholesterol and triglyceride levels for 35 patients with TRD who did not respond to NT with 205 non-TRD patients who responded to an 8-week open trial of fluoxetine. Furthermore, with the use of logistic regression, we tested whether baseline cholesterol levels predicted clinical response to NT in the patients with TRD. Results: Patients with TRD had higher triglyceride levels at baseline compared with depressed patients without TRD. Cholesterol defined as a dichotomous variable being elevated if equal to or greater than 200 mg/dl, predicted poor response to a 6-week open trial of NT in patients with TRD. Conclusions: The results of this study confirm the relationship between hypercholesterolemia and poor outcome in the treatment of MDD for patients with TRD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Serum Cholesterol in Treatment-Resistant Depression

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Buydens-Branchey et al (2000) found that the lipid fraction associated with neuroendocrine indices of reduced serotonin function was low HDL-C, not TC or LDL-C. Although other studies have suggested that serum cholesterol may be a marker for central serotonergic activity (Steegmans et al, 1996;Terao et al, 2000;Vevera et al, 2005), it is worth noting that Hibbeln et al (1998) found a strong correlation between brain serotonin metabolites and omega-3 fatty acids, a finding suggesting that, in previous studies, cholesterol was acting as a ''surrogate marker'' for omega-3 fatty acids (Hibbeln et al, 2000). Kaplan et al (1997) proposed a plausible evolutionary rationale for the cholesterol-serotonin hypothesis.…”

Section: Neural Mechanismsmentioning

confidence: 99%

Cholesterol in coronary heart disease and psychiatric disorders: Same or opposite effects on morbidity risk?

Troisi

2009

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…The former include 5-hydroxytryptophan (Meltzer et al 1984;Koyama and Meltzer 1986), l-tryptophan (Heninger et al 1984;Price et al 1991), fenfluramine (Lopez-Ibor et al 1989;O'Keane and Dinan 1991), and clomipramine (Laakman et al 1984), while the latter include metachlorophenylpiperazine (m-CPP) (Kahn and Wetzler 1991;Terao et al 1997Terao et al , 2000aTerao et al , 2000b, ipsapirone (Lesch et al 1990) and others.…”

Section: Introductionmentioning

confidence: 99%